Phase III trial with SGLT2 inhibitor meets primary endpoint in HFpEF

News - July 6, 2021

EMPEROR-Preserved met its primary endpoint and showed a significant risk reduction with empagliflozin for the composite primary endpoint of time to first event of CV death or HF hospitalization in patients with HFpEF, with or without T2DM. The safety profile was consistent with the known safety profile of empagliflozin. The EMPEROR-Preserved trial was a phase III, double-blind randomized trial that investigated the safety and efficacy of empagliflozin 10 mg compared to placebo in 5988 patients with HFpEF. Full results of EMPEROR-Preserved will be presented at the ESC congress 2021 on August 27.

The EMPEROR-Reduced trial previously showed that empagliflozin significantly reduced the combined relative risk of cardiovascular death or HF hospitalization by 25% compared to placebo in patients with HFrEF. Empagliflozin was recently approved by the European Commission for the treatment of adults with HFrEF in Europe. The results from EMPEROR-Preserved and EMPEROR-Reduced together indicate that empagliflozin has beneficial effects on outcomes in the full HF spectrum.

Source: press release Boehringer Ingelheim, July 6, 2021

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free